180 results on '"Buisseret L"'
Search Results
2. Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
3. 179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
4. 19P The prognostic value of soluble CD73 in advanced triple-negative breast cancer: An exploratory analysis of the SYNERGY trial
5. 176P Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
6. 195P IMMUcan: Toward a better understanding of the tumor microenvironment to inform precision oncology approaches
7. Immuno-oncology-101: overview of major concepts and translational perspectives
8. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
9. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
10. 15P Portraying HER2-positive breast cancer heterogeneity with spatial transcriptomics
11. 59P Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma
12. 34P Investigating morphological heterogeneity in luminal breast cancer integrating artificial intelligence and spatial transcriptomics
13. 224P Immune characterization of de novo metastatic breast cancer
14. LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
15. LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)
16. 290P Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
17. 257P Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
18. 253P Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy
19. 98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase
20. PO-1185 Targeting therapy-resistant metastatic clones with SBRT in oligoprogressive breast cancer
21. Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
22. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
23. Impact of HIV infection on baseline characteristics and survival of women with breast cancer: a systematic review and meta-analysis
24. O03.3 Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial
25. 72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast
26. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
27. 2274P Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
28. 44P The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis
29. 84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial
30. 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
31. 165P Immune characterization of the de novo oligometastatic breast cancer
32. 188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis
33. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
34. First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
35. 95P - Infrared Imaging: a Potential New Tool to Characterize Lymphocytic Infiltration in Human Breast Cancer
36. 86P - The Composition and Organization of Lymphocytes Infiltrating Human Breast Cancer
37. SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
38. Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort
39. Abstract PD5-09: Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up
40. Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis
41. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
42. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
43. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
44. Abstract PD6-05: Distinct tumor microenvironments stratify triple negative breast cancer into immune subtypes
45. Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial
46. Immune Infiltration in Invasive Lobular Breast Cancer
47. Distinct immune microenvironments stratify triple-negative breast cancer and predict outcome
48. Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial
49. Abstract P6-10-03: KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)
50. Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.